Pharmacology and cellular/molecular mechanisms of action of aspirin and Non-aspirin NSAIDs in colorectal cancer

Best Practice and Research: Clinical Gastroenterology

Volumn 25, Issue 4-5, 2011, Pages 473-484

  Schrör, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Aspirin; Colorectal cancer; Non aspirin NSAIDs; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ASPIRIN TRIGGERED LIPOXIN; BETA CATENIN; CELECOXIB; CELL PROTEIN; CERAMIDE; COCARCINOGEN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; K RAS PROTEIN; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; NSAID ACTIVATED GENE 1 PROTEIN; PROSTAGLANDIN E2; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SULINDAC; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLEEDING; CANCER STEM CELL; CELL PROLIFERATION; COLON CARCINOGENESIS; COLORECTAL CANCER; ENZYME INHIBITION; GENE ACTIVATION; GENE MUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIFESTYLE MODIFICATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION INHIBITION; TRANSCRIPTION REGULATION; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; SIGNAL TRANSDUCTION;

EID: 82455188359     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2011.10.016     Document Type: Article

References (96)

1. E.R. Fearon Molecular genetics of colorectal cancer Annu Rev Pathol 6 2011 479 507
2. F.J. Abdul Khalek, G.I. Gallicano, and L. Mishra Colon cancer stem cells Gastrointest Cancer Res Suppl. 1 2010 S16 S23
3. G.A. Kune, S. Kune, and L.F. Watson Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study Cancer Res 48 15 1988 4399 4404
4. P.M. Rothwell, F.G. Fowkes, J.F. Belch, H. Ogawa, C.P. Warlow, and T.W. Meade Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 9759 2011 31 41
5. F.V. Din, E. Theodoratou, S.M. Farrington, A. Tenesa, R.A. Barnetson, and R. Cetnarskyj Effect of aspirin and NSAIDs on risk and survival from colorectal cancer Gut 59 12 2010 1670 1679
6. F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, and P. Celano Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 328 18 1993 1313 1316 (Pubitemid 23131373)
7. P.J. Limburg, M.R. Mahoney, K.L. Ziegler, S.J. Sontag, R.E. Schoen, and R. Benya Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention Cancer Prev Res (Phila) 4 2 2011 259 269
8. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, and G.B. Gordon The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 26 2000 1946 1952 (Pubitemid 30419089)
9. C.E. Eberhart, R.J. Coffey, A. Radhika, F.M. Giardiello, S. Ferrenbach, and R.N. DuBois Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas Gastroenterology 107 4 1994 1183 1188 (Pubitemid 24294584)
10. L.J. Marnett Aspirin and the potential role of prostaglandins in colon cancer Cancer Res 52 20 1992 5575 5589
11. W. Kutchera, D.A. Jones, N. Matsunami, J. Groden, T.M. McIntyre, and G.A. Zimmerman Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect Proc Natl Acad Sci USA 93 10 1996 4816 4820 (Pubitemid 26162834)
12. S.L. Kargman, G.P. O'Neill, P.J. Vickers, J.F. Evans, J.A. Mancini, and S. Jothy Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer Cancer Res 55 12 1995 2556 2559
13. D. Wang, and R.N. Dubois The role of COX-2 in intestinal inflammation and colorectal cancer Oncogene 29 6 2010 781 788
14. C.S. Williams, W. Smalley, and R.N. DuBois Aspirin use and potential mechanisms for colorectal cancer prevention J Clin Invest 100 6 1997 1325 1329 (Pubitemid 27425755)
15. G.N. Levy Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer FASEB J 11 4 1997 234 247 (Pubitemid 27118324)
16. B. Rigas, and S.J. Shiff Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: evidence for PHS-dependent and PHS-independent mechanisms Apoptosis 4 5 1999 373 381
17. K. Schrör Acetylsalicylic acid 2009 Wiley-VCH Verlag Weinheim p. 376
18. R. Hanif, A. Pittas, Y. Feng, M.I. Koutsos, L. Qiao, and L. Staiano-Coico Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway Biochem Pharmacol 52 2 1996 237 245 (Pubitemid 26233752)
19. H.G. Yu, J.A. Huang, Y.N. Yang, H. Huang, H.S. Luo, and J.P. Yu The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells Eur J Clin Invest 32 11 2002 838 846 (Pubitemid 35356936)
20. R.N. DuBois, and W.E. Smalley Cyclooxygenase, NSAIDs, and colorectal cancer J Gastroenterol 31 6 1996 898 906 (Pubitemid 27042276)
21. K.C. Zimmermann, M. Sarbia, A.A. Weber, F. Borchard, H.E. Gabbert, and K. Schrör Cyclooxygenase-2 expression in human esophageal carcinoma Cancer Res 59 1 1999 198 204 (Pubitemid 29062978)
22. A. Ristimäki, N. Honkanen, H. Jänkälä, P. Sipponen, and M. Härkönen Expression of cyclooxygenase-2 in human gastric carcinoma Cancer Res 57 7 1997 1276 1280 (Pubitemid 27152551)
23. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nat Med 10 8 2004 789 799 (Pubitemid 39070849)
24. B.T. MacDonald, K. Tamai, and X. He Wnt/β-catenin signaling: components, mechanisms, and diseases Dev Cell 17 1 2009 9 26
25. A.J. Rowan, H. Lamlum, M. Ilyas, J. Wheeler, J. Straub, and A. Papadopoulou APC mutations in sporadic colorectal tumors: a mutational "hotspot" and interdependence of the "two hits" Proc Natl Acad Sci USA 97 7 2000 3352 3357 (Pubitemid 30183306)
26. K.W. Kinzler, and B. Vogelstein Lessons from hereditary colorectal cancer Cell 87 2 1996 159 170 (Pubitemid 26358996)
27. M.D. Castellone, H. Teramoto, and J.S. Gutkind Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection Cancer Res 66 23 2006 11085 11088 (Pubitemid 46009929)
28. T.C. He, T.A. Chan, B. Vogelstein, and K.W. Kinzler PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 99 3 1999 335 345 (Pubitemid 29519912)
29. L.J. Marnett, and R.N. DuBois COX-2: a target for colon cancer prevention Annu Rev Pharmacol Toxicol 42 2002 55 80 (Pubitemid 34160519)
30. H. Sano, Y. Kawahito, R.L. Wilder, A. Hashiramoto, S. Mukai, and K. Asai Expression of cyclooxygenase-1 and -2 in human colorectal cancer Cancer Res 55 17 1995 3785 3789
31. D. Nie, and K.V. Honn Cyclooxygenase, lipoxygenase and tumor angiogenesis Cell Mol Life Sci 59 5 2002 799 807 (Pubitemid 34628241)
32. M. Tsujii, S. Kawano, and R.N. DuBois Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential Proc Natl Acad Sci USA 94 7 1997 3336 3340 (Pubitemid 27157312)
33. T. Fujita, M. Matsui, K. Takaku, H. Uetake, W. Ichikawa, and M.M. Taketo Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas Cancer Res 58 21 1998 4823 4826 (Pubitemid 28503676)
34. S. Ogino, G.J. Kirkner, K. Nosho, N. Irahara, S. Kure, and K. Shima Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer Clin Cancer Res 14 24 2008 8221 8227
35. K.M. Sheehan, K. Sheahan, D.P. O'Donoghue, F. MacSweeney, R.M. Conroy, and D.J. Fitzgerald The relationship between cyclooxygenase-2 expression and colorectal cancer JAMA 282 13 1999 1254 1257 (Pubitemid 29468497)
36. R. Fux, M. Schwab, K.P. Thon, C.H. Gleiter, and P. Fritz Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival Clin Cancer Res 11 13 2005 4754 4760 (Pubitemid 41557195)
37. S. Pugh, and G.A. Thomas Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2 Gut 35 5 1994 675 678 (Pubitemid 24163797)
38. D. Wang, and R.N. Dubois Prostaglandins and cancer Gut 55 1 2006 115 122 (Pubitemid 41820645)
39. M. Sonoshita, K. Takaku, N. Sasaki, Y. Sugimoto, F. Ushikubi, and S. Narumiya Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice Nat Med 7 9 2001 1048 1051 (Pubitemid 32937386)
40. J. Shao, C. Jung, C. Liu, and H. Sheng Prostaglandin E2 Stimulates the beta-catenin/T cell factor-dependent transcription in colon cancer J Biol Chem 280 28 2005 26565 26572 (Pubitemid 41022254)
41. C.M. Balch, P.A. Dougherty, G.A. Cloud, and A.B. Tilden Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients Surgery 95 1 1984 71 77 (Pubitemid 14215461)
42. W. Qiu, X. Wang, B. Leibowitz, H. Liu, N. Barker, and H. Okada Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis Proc Natl Acad Sci USA 107 46 2010 20027 20032
43. T.J. Maier, A. Janssen, R. Schmidt, G. Geisslinger, and S. Grösch Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells FASEB J 19 10 2005 1353 1355 (Pubitemid 41113747)
44. L. Deng, S. Hu, A.R. Baydoun, J. Chen, X. Chen, and X. Cong Aspirin induces apoptosis in mesenchymal stem cells requiring Wnt/beta-catenin pathway Cell Prolif 42 6 2009 721 730
45. K.K. Wu Salicylates and their spectrum of activties Anti-Inflamm Anti-Allergy Agents Med Chem 6 2007 278 292
46. A.T. Chan, S. Ogino, and C.S. Fuchs Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356 21 2007 2131 2142 (Pubitemid 47010839)
47. A.T. Chan, S. Ogino, and C.S. Fuchs Aspirin use and survival after diagnosis of colorectal cancer JAMA 302 6 2009 649 658
48. S.M. Fischer, E. Hawk, and R.A. Lubet Non-steroidal anti-inflammatory drugs and coxibs in chemoprevention: a commentary based primarily on animal studies Cancer Prev Res (Phila) 2011
49. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, and E. Kwong Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 5 1996 803 809 (Pubitemid 26404280)
50. P.C. Chulada, M.B. Thompson, J.F. Mahler, C.M. Doyle, B.W. Gaul, and C. Lee Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res 60 17 2000 4705 4708
51. T.D. Warner, and J.A. Mitchell Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic FASEB J 18 7 2004 790 804 (Pubitemid 38544498)
52. J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, and J.R. Vane Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci USA 90 24 1993 11693 11697 (Pubitemid 24008705)
53. T.O. Frommel, M. Dyavanapalli, T. Oldham, N. Kazi, H. Lietz, and Y. Liao Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients Clin Cancer Res 3 2 1997 209 213 (Pubitemid 27107296)
54. C.J. Barnes, R.L. Hamby-Mason, W.E. Hardman, I.L. Cameron, K.V. Speeg, and M. Lee Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon Cancer Epidemiol Biomarkers Prev 8 4 Pt 1 1999 311 315 (Pubitemid 29193902)
55. B.F. Cole, R.F. Logan, S. Halabi, R. Benamouzig, R.S. Sandler, and M.J. Grainge Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials J Natl Cancer Inst 101 4 2009 256 266
56. L.A. Garcia-Rodriguez, and A.C. H.- Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs Epidemiology 12 1 2001 88 93
57. A.T. Chan, E.L. Giovannucci, J.A. Meyerhardt, E.S. Schernhammer, K. Wu, and C.S. Fuchs Aspirin dose and duration of use and risk of colorectal cancer in men Gastroenterology 134 1 2008 21 28 (Pubitemid 350309311)
58. C.J. Loveridge The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kappaB Oncogene 27 18 2008 2648 2655 (Pubitemid 351550873)
59. R. Haas, W.D. Parker Jr., D. Stumpf, and L.A. Eguren Salicylate-induced loose coupling: protonmotive force measurements Biochem Pharmacol 34 6 1985 900 902 (Pubitemid 15107187)
60. S.J. Baek, K.S. Kim, J.B. Nixon, L.C. Wilson, and T.E. Eling Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities Mol Pharmacol 59 4 2001 901 908 (Pubitemid 32274020)
61. G. Iguchi, K. Chrysovergis, S.H. Lee, S.J. Baek, R. Langenbach, and T.E. Eling A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2 Cancer Lett 282 2 2009 152 158
62. J. Claria, M.H. Lee, and C.N. Serhan Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation Mol Med 2 5 1996 583 596 (Pubitemid 26353107)
63. T. Morris, M. Stables, A. Hobbs, P. de Souza, P. Colville-Nash, and T. Warner Effects of low-dose aspirin on acute inflammatory responses in humans J Immunol 183 3 2009 2089 2096
64. N.B. Janakiram, and C.V. Rao Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer Curr Mol Med 9 5 2009 565 579
65. T.E. Eling, D.C. Thompson, G.L. Foureman, J.F. Curtis, and M.F. Hughes Prostaglandin H synthase and xenobiotic oxidation Annu Rev Pharmacol Toxicol 30 1990 1 45
66. B.S. Reddy, C.V. Rao, A. Rivenson, and G. Kelloff Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats Carcinogenesis 14 8 1993 1493 1497 (Pubitemid 23249348)
67. B.S. Reddy, T. Kawamori, R.A. Lubet, V.E. Steele, G.J. Kelloff, and C.V. Rao Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process Cancer Res 59 14 1999 3387 3391 (Pubitemid 29334497)
68. S. Bousserouel, F. Gosse, M. Bouhadjar, L. Soler, J. Marescaux, and F. Raul Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis Oncol Rep 23 2 2010 511 517
69. P.A. Craven, and F.R. DeRubertis Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis Carcinogenesis 13 4 1992 541 546
70. D.E. Corpet, and F. Pierre How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men Eur J Cancer 41 13 2005 1911 1922 (Pubitemid 41557677)
71. B. Ogretmen, and Y.A. Hannun Biologically active sphingolipids in cancer pathogenesis and treatment Nat Rev Cancer 4 8 2004 604 616 (Pubitemid 39025055)
72. S. Ponnusamy, M. Meyers-Needham, C.E. Senkal, S.A. Saddoughi, D. Sentelle, and S.P. Selvam Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance Future Oncol 6 10 2010 1603 1624
73. T. Kawamori, W. Osta, K.R. Johnson, B.J. Pettus, J. Bielawski, and T. Tanaka Sphingosine kinase 1 is up-regulated in colon carcinogenesis FASEB J 20 2 2006 386 388 (Pubitemid 46671180)
74. K.J. French, R.S. Schrecengost, B.D. Lee, Y. Zhuang, S.N. Smith, and J.L. Eberly Discovery and evaluation of inhibitors of human sphingosine kinase Cancer Res 63 18 2003 5962 5969 (Pubitemid 37187498)
75. T. Kawamori, T. Kaneshiro, M. Okumura, S. Maalouf, A. Uflacker, and J. Bielawski Role for sphingosine kinase 1 in colon carcinogenesis FASEB J 23 2 2009 405 414
76. T. Ulrych, A. Böhm, A. Polzin, G. Daum, R.M. Nüsing, and G. Geisslinger Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation J Thromb Haemost 9 4 2011 790 798
77. S. Dihlmann, A. Siermann, and M. von Knebel Doeberitz The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling Oncogene 20 5 2001 645 653 (Pubitemid 32156189)
78. G.A. Piazza, A.L. Rahm, M. Krutzsch, G. Sperl, N.S. Paranka, and P.H. Gross Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis Cancer Res 55 14 1995 3110 3116
79. G.A. Piazza, D.S. Alberts, L.J. Hixson, N.S. Paranka, H. Li, and T. Finn Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res 57 14 1997 2909 2915 (Pubitemid 27315038)
80. D.S. Alberts, L. Hixson, D. Ahnen, C. Bogert, J. Einspahr, and N. Paranka Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 22 1995 18 23
81. T. Takayama, H. Nagashima, M. Maeda, S. Nojiri, M. Hirayama, and Y. Nakano Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps Clin Cancer Res 17 11 2011 3803 3811
82. H.N. Tinsley, B.D. Gary, J. Thaiparambil, N. Li, W. Lu, and Y. Li Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition Cancer Prev Res (Phila) 3 10 2010 1303 1313
83. D. Das, N. Arber, and J.A. Jankowski Chemoprevention of colorectal cancer Digestion 76 1 2007 51 67 (Pubitemid 47608860)
84. J.R. Marshall Nutrition and colon cancer prevention Curr Opin Clin Nutr Metab Care 12 5 2009 539 543
85. R.A. Hubner, K.R. Muir, J.F. Liu, R.F. Logan, M.J. Grainge, and R.S. Houlston Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention Clin Cancer Res 14 8 2008 2303 2309 (Pubitemid 351551061)
86. F.L. Meyskens Jr., C.E. McLaren, D. Pelot, S. Fujikawa-Brooks, P.M. Carpenter, and E. Hawk Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila) 1 1 2008 32 38
87. U. Stein, F. Arlt, J. Smith, U. Sack, P. Herrmann, and W. Walther Intervening in beta-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis Neoplasia 13 2 2011 131 144
88. M. Holmes-McNary Nuclear factor kappa B signaling in catabolic disorders Curr Opin Clin Nutr Metab Care 5 3 2002 255 263
89. L.A. Stark, F.V. Din, R.M. Zwacka, and M.G. Dunlop Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells FASEB J 15 7 2001 1273 1275
90. F.V. Din, L.A. Stark, and M.G. Dunlop Aspirin-induced nuclear translocation of NFkappaB and apoptosis in colorectal cancer is independent of p53 status and DNA mismatch repair proficiency Br J Cancer 92 6 2005 1137 1143 (Pubitemid 40546681)
91. Y. Takada, A. Bhardwaj, P. Potdar, and B.B. Aggarwal Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation Oncogene 23 57 2004 9247 9258 (Pubitemid 40069695)
92. R.R. Brady, C.J. Loveridge, M.G. Dunlop, and L.A. Stark c-Src dependency of NSAID-induced effects on NF-kappaB-mediated apoptosis in colorectal cancer cells Carcinogenesis 32 7 2011 1069 1077
93. S. Martin, D.C. Phillips, K. Szekely-Szucs, L. Elghazi, F. Desmots, and J.A. Houghton Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae Cancer Res 65 24 2005 11447 11458 (Pubitemid 41821702)
94. K.M. Kim, J.J. Song, J.Y. An, Y.T. Kwon, and Y.J. Lee Pretreatment of acetylsalicylic acid promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down-regulating BCL-2 gene expression J Biol Chem 280 49 2005 41047 41056 (Pubitemid 41780600)
95. J. Rüschoff, S. Wallinger, W. Dietmaier, T. Bocker, G. Brockhoff, and F. Hofstädter Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection Proc Natl Acad Sci USA 95 19 1998 11301 11306 (Pubitemid 28450123)
96. C.S. Hsu, and Y. Li Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention Biochem Biophys Res Commun 293 2 2002 705 709 (Pubitemid 34687244)